- Immunotherapy improves survival for people with relapsed mesothelioma
- JHMRF Pump-Priming Grants 2018
- Science workshop a first
- An invitation to join us for Action Mesothelioma Day 2018
- JHMRF Pump Priming Grant
- JHMRF to hold scientific workshop
- JHMRF spends £450,000 on new research projects
- Oncologist researcher makes conference debut with help of JHMRF
- Lily presents to South African conference
- Radiotherapy helped one in three in largest ever trial
- Hope in mesothelioma research
- The SYSTEMS Study
- Top ten mesothelioma research priorities announced
- JHMRF funds new research projects
- COMMAND study investigates mesothelioma drug
- NIHR welcomes proposals for research into mesothelioma
- Survey launched to help identify mesothelioma treatment uncertainties
- University of Leicester leads groundbreaking mesothelioma trials
- Phase II TroVax® trial begins
- Fund awards £120,000 for chemotherapy research
- Research portfolio update
- Clinical Trials in Mesothelioma
- New clinical fellowship funded
- Research Award 2012
Immunotherapy improves survival for people with relapsed mesothelioma
March 1, 2021
It was recently reported by Cancer Research UK, that people with an aggressive form of lung cancer that’s come back after treatment, leaving them with limited options, could live longer when treated with an immunotherapy currently available for several types of cancer.
The trial, funded by Cancer Research UK’s Stand Up To Cancer campaign, found that the immunotherapy drug nivolumab increased survival and made the disease more stable for patients with relapsed mesothelioma when compared to those in the placebo group. This is the first study to show that a treatment has been able to improve survival in patients with mesothelioma that’s come back after chemotherapy.
You can read the full article on the Cancer Research UK website.
Posted in research news
Leave a comment